Isotopes Used in Nuclear Medicine

Why This Matters

Nuclear medicine sits at the intersection of physics and healthcare, and understanding medical isotopes means grasping the fundamental principles that make them useful: decay modes, half-lives, radiation types, and tissue interactions. You're being tested not just on which isotope treats which condition, but on why a particular isotope's physical properties make it ideal for a specific application. The difference between a diagnostic isotope and a therapeutic one comes down to the type of radiation emitted and how that radiation interacts with biological tissue.

When you encounter exam questions about medical isotopes, think in terms of mechanisms: gamma emitters penetrate tissue and reach detectors for imaging, while beta emitters deposit energy locally to destroy targeted cells. Half-life determines whether an isotope is practical for imaging (short half-lives minimize patient dose) or therapy (longer half-lives allow sustained treatment). Don't just memorize that Technetium-99m is used for SPECT—know that its 6-hour half-life and pure gamma emission make it nearly perfect for diagnostic imaging with minimal patient radiation burden.

---

Gamma Emitters for Diagnostic Imaging

These isotopes share a common feature: they emit gamma radiation that passes through tissue to reach external detectors. The ideal diagnostic isotope produces clear images while delivering the lowest possible radiation dose to the patient.

Technetium-99m

• Half-life of 6 hours—short enough to minimize radiation exposure, long enough for imaging procedures and biodistribution
• Pure gamma emitter at 140 keV, an energy optimized for gamma camera detection and tissue penetration
• Most widely used medical isotope, accounting for ~80% of all nuclear medicine procedures, particularly SPECT imaging

Iodine-123

• Half-life of 13.2 hours—provides optimal imaging window for thyroid studies with lower dose than Iodine-131
• Gamma emission at 159 keV makes it ideal for SPECT imaging of thyroid function and structure
• Preferentially absorbed by thyroid tissue due to iodine's biological role, enabling organ-specific imaging

Indium-111

• Half-life of 2.8 days—allows for delayed imaging to track slow biological processes like white blood cell migration
• Dual gamma emission at 171 and 245 keV enables imaging with good tissue contrast
• Used for labeling cells and antibodies, making it valuable for infection detection and immunoscintigraphy

Thallium-201

• Half-life of 73 hours—provides flexibility for stress-rest cardiac imaging protocols
• Behaves as a potassium analog, accumulating in viable myocardial tissue proportional to blood flow
• Gamma emission allows assessment of myocardial perfusion and viability in coronary artery disease

---

Positron Emitters for PET Imaging

Positron emission tomography relies on a fundamentally different detection mechanism: positrons annihilate with electrons, producing two 511 keV gamma rays traveling in opposite directions, enabling precise localization through coincidence detection.

Fluorine-18

• Half-life of 110 minutes—requires on-site cyclotron production or rapid delivery, but provides excellent image resolution
• Positron emitter that enables PET imaging with spatial resolution superior to SPECT techniques
• $^{18}$F-FDG (fluorodeoxyglucose) exploits elevated glucose metabolism in cancer cells, making it the gold standard for oncologic imaging

Gallium-67

• Half-life of 78 hours—allows delayed imaging at 48-72 hours when tumor-to-background ratio is optimal
• Accumulates in rapidly dividing cells and inflammatory tissue by binding to transferrin receptors
• Multiple gamma emissions enable imaging of lymphoma, infections, and inflammatory conditions

---

Beta Emitters for Targeted Therapy

Therapeutic isotopes deliver cytotoxic radiation directly to diseased tissue. Beta particles deposit their energy within a few millimeters of the source, destroying nearby cells while sparing distant healthy tissue.

Iodine-131

• Half-life of 8.02 days—long enough for therapeutic effect, short enough to limit prolonged radiation exposure
• Beta emission ($\beta^-$) delivers cytotoxic dose to thyroid tissue; accompanying gamma allows post-treatment imaging
• Selectively concentrated in thyroid due to iodine's biological role, enabling treatment of hyperthyroidism and differentiated thyroid cancer

Yttrium-90

• Half-life of 64 hours—provides sustained local irradiation while allowing eventual clearance
• Pure beta emitter with high energy (2.3 MeV max), penetrating 5-10 mm in tissue for effective tumor destruction
• Used in radioembolization for liver cancer, where microspheres lodge in tumor vasculature and deliver localized radiation

Samarium-153

• Half-life of 46.3 hours—balances therapeutic duration with manageable radiation safety considerations
• Beta emission targets bone metastases by binding to hydroxyapatite at sites of increased bone turnover
• Provides palliative pain relief in patients with widespread skeletal metastases from prostate or breast cancer

---

Specialized Diagnostic Applications

Some isotopes fill unique niches based on their specific physical or biological properties. These applications demonstrate how matching isotope characteristics to clinical needs drives nuclear medicine innovation.

Xenon-133

• Half-life of 5.2 days—suitable for pulmonary studies but requires proper ventilation systems for exhaled gas
• Inert gas that distributes according to ventilation, enabling real-time assessment of regional lung function
• Gamma emission at 81 keV allows imaging of ventilation patterns to detect pulmonary embolism and COPD

---

Quick Reference Table

---

Self-Check Questions

1. Which two isotopes are both used for thyroid applications, and what property of their radiation makes one preferred for imaging versus therapy?

2. A patient needs imaging of a suspected infection that may take 48-72 hours to localize. Which isotope's half-life makes it suitable for this delayed imaging protocol, and why would Technetium-99m be inappropriate?

3. Compare and contrast the detection mechanisms of SPECT (using Tc-99m) and PET (using F-18). How does the physics of positron annihilation provide superior spatial resolution?

4. An FRQ asks you to explain why Yttrium-90 is preferred over Iodine-131 for treating liver tumors. What properties of Y-90's radiation emission make it more suitable for this application?

5. Which isotopes would you classify as "theranostic" (capable of both therapy and diagnosis), and what physical property enables this dual function?